- Voluntis enters into a license agreement with Eisai to design & develop DTx for patients and healthcare professionals to support cancer treatment, utilizing the Theraxium technology platform
- The DTx will be designed with the intent to be commercialized in the US, Japan and EU, which will boost Voluntis’ pipeline and global footprint
- Additionally, the partners will explore other opportunities to develop, evaluate and commercialize DTx in the field of neurology, notably AD and dementia
Click here to read full press release/ article | Ref: Businesswire | Image: Voluntis
The post Voluntis Collaborates with Eisai to Develop Digital Therapeutics for Oncology Patients first appeared on PharmaShots.